Tirzepatide ranks first for average weight-loss efficacy, while semaglutide and newer oral options may suit different medical needs and preferences. A clinician should match treatment to your health history, eligibility, interactions, and access.
Tirzepatide leads on reported average weight loss, though suitability still depends on individual medical factors and access.
Supplied reviews and medical reporting consistently identify tirzepatide as the strongest current option for average weight reduction, with reported losses up to 22.5%.Semaglutide offers strong, well-established weight loss with a weekly injection and a dedicated obesity-treatment brand.
Supplied sources report average weight loss around 15% and identify Wegovy as a leading FDA-approved option for chronic weight management.Orforglipron is the leading oral convenience option, but its newer evidence base is less established than injectable leaders.
Supplied sources describe Foundayo as an FDA-approved once-daily oral option for chronic weight management and note comparable oral-trial digestive side effects.Semaglutide tablets improve convenience, but supplied evidence supports less weight loss than the leading injectable choices.
Supplied sources describe oral semaglutide as an available tablet option and report moderate weight loss for semaglutide-based therapies, with oral-trial tolerability considerations.Liraglutide remains an established weight-management option, but supplied sources place its average weight loss below newer therapies.
Supplied medical guides identify Saxenda as an FDA-approved weight-loss medication with reported average losses in the 5–10% range.Three independent write-ins unlock an honorable mention. The 10 strongest active mentions are shown; inactive mentions archive after 12 months. At 25 monthly votes, a contender enters a scoring review for possible top-five promotion.
No honorable mentions yet. Repeated write-ins merge automatically.
Commercial-link disclosure: Some shopping and booking links may become affiliate links when a partner relationship is active. SummaRank may then earn a commission from qualifying purchases or bookings, at no added cost to you. Commercial availability never affects scores or rank order.
The five criteria create the AI baseline. The community adjustment is then added or subtracted to produce the current published score.
| Criterion | #1Tirzepatide (Zepbound) | #2Semaglutide (Wegovy) | #3Orforglipron (Foundayo) | #4Semaglutide (Rybelsus) | #5Liraglutide (Saxenda) |
|---|---|---|---|---|---|
| 98 | 86 | 72 | 60 | 58 | |
| 94 | 96 | 76 | 88 | 91 | |
| 88 | 88 | 92 | 84 | 62 | |
| 94 | 95 | 93 | 84 | 94 | |
| 78 | 75 | 68 | 66 | 72 | |
| AI baseline scoreWeighted criteria result | 92.6 | 88.7 | 79.5 | 74.6 | 72.2 |
| Community adjustmentVote-share influence | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current published scoreBaseline + community | 93 | 89 | 80 | 75 | 72 |
Select any two contenders above.
We’ll line up what matters.
Tirzepatide
Semaglutide
GLP-1/GIP dual agonist
GLP-1 receptor agonist
Weekly injection
Weekly injection
Up to 22.5% reported average loss
About 15% reported average loss
Chronic weight management
Chronic weight management
Weighted comparison of reported weight-loss efficacy, evidence quality, convenience, regulatory fit, and tolerability using supplied medical, academic, and editorial evidence. Brand names are shown where relevant.
The five criteria create the AI baseline. The community adjustment is then added or subtracted to produce the current published score.
| Criterion | #1Tirzepatide (Zepbound) | #2Semaglutide (Wegovy) | #3Orforglipron (Foundayo) | #4Semaglutide (Rybelsus) | #5Liraglutide (Saxenda) |
|---|---|---|---|---|---|
| 98 | 86 | 72 | 60 | 58 | |
| 94 | 96 | 76 | 88 | 91 | |
| 88 | 88 | 92 | 84 | 62 | |
| 94 | 95 | 93 | 84 | 94 | |
| 78 | 75 | 68 | 66 | 72 | |
| AI baseline scoreWeighted criteria result | 92.6 | 88.7 | 79.5 | 74.6 | 72.2 |
| Community adjustmentVote-share influence | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current published scoreBaseline + community | 93 | 89 | 80 | 75 | 72 |